Product Description
Ziresovir (RO-0529, AK0529) is reported here for the first time as a promising respiratory syncytial virus (RSV) fusion (F) protein inhibitor that currently is in phase 2 clinical trials. This article describes the process of RO-0529 as a potent, selective, and orally bioavailable RSV F protein inhibitor and highlights the in vitro and in vivo anti-RSV activities and pharmacokinetics in animal species. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31194544/)
Mechanisms of Action: FP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ark
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Respiratory Syncytial Virus Infections
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AK0529-3004 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-12-31 |
|
| AIRFLO | P3 |
Completed |
Respiratory Syncytial Virus Infections |
2022-01-21 |
|
| CTR20200215 | P3 |
Not yet recruiting |
Respiratory Syncytial Virus Infections |
None |
|
| CTR20181808 | P2 |
Recruiting |
Respiratory Syncytial Virus Infections |
None |